Jenburkt Pharmaceuticals Ltd
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]
- Market Cap ₹ 579 Cr.
- Current Price ₹ 1,312
- High / Low ₹ 1,375 / 643
- Stock P/E 19.1
- Book Value ₹ 357
- Dividend Yield 1.17 %
- ROCE 26.2 %
- ROE 19.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 25.5%
Cons
- The company has delivered a poor sales growth of 2.97% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
69 | 76 | 85 | 94 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 | 148 | |
59 | 65 | 70 | 77 | 84 | 91 | 98 | 99 | 89 | 97 | 106 | 109 | 111 | |
Operating Profit | 10 | 12 | 15 | 16 | 20 | 24 | 25 | 20 | 20 | 27 | 30 | 33 | 38 |
OPM % | 15% | 15% | 18% | 18% | 19% | 21% | 20% | 17% | 18% | 22% | 22% | 23% | 25% |
1 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | |
Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 2 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 9 | 10 | 14 | 17 | 20 | 25 | 27 | 21 | 22 | 30 | 33 | 35 | 41 |
Tax % | 30% | 27% | 33% | 36% | 34% | 32% | 26% | 30% | 24% | 25% | 25% | 26% | |
6 | 8 | 10 | 11 | 14 | 17 | 20 | 15 | 16 | 22 | 25 | 26 | 30 | |
EPS in Rs | 13.38 | 16.15 | 20.76 | 23.19 | 29.06 | 37.50 | 43.14 | 32.40 | 35.95 | 48.59 | 55.76 | 58.87 | 68.66 |
Dividend Payout % | 31% | 32% | 30% | 31% | 28% | 24% | 24% | 25% | 28% | 25% | 26% | 26% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 3% |
3 Years: | 9% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 6% |
3 Years: | 16% |
TTM: | 24% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 27% |
3 Years: | 35% |
1 Year: | 92% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 20% |
3 Years: | 20% |
Last Year: | 19% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 |
Reserves | 18 | 23 | 29 | 36 | 50 | 57 | 73 | 75 | 94 | 113 | 118 | 141 | 153 |
5 | 2 | 7 | 5 | 6 | 0 | 7 | 3 | 5 | 7 | 3 | 0 | 2 | |
22 | 15 | 21 | 12 | 16 | 16 | 18 | 21 | 17 | 18 | 16 | 19 | 22 | |
Total Liabilities | 49 | 44 | 61 | 58 | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 181 |
14 | 14 | 12 | 12 | 11 | 10 | 10 | 12 | 11 | 11 | 10 | 10 | 14 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 |
Investments | 0 | 0 | 0 | 1 | 2 | 5 | 5 | 4 | 7 | 8 | 11 | 17 | 32 |
34 | 30 | 49 | 45 | 64 | 62 | 87 | 88 | 103 | 123 | 119 | 136 | 135 | |
Total Assets | 49 | 44 | 61 | 58 | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 181 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 11 | 9 | 8 | 10 | 16 | 13 | 15 | 19 | 9 | 17 | 8 | |
-1 | 0 | 1 | -0 | -10 | 1 | -11 | -3 | -19 | -1 | 3 | -1 | |
0 | -7 | 1 | -5 | 1 | -18 | -2 | -11 | -1 | -6 | -21 | -7 | |
Net Cash Flow | 3 | 5 | 11 | 2 | 1 | -1 | 0 | 1 | -0 | 3 | -1 | 0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 32 | 26 | 32 | 23 | 32 | 40 | 68 | 55 | 47 | 45 | 45 | 50 |
Inventory Days | 123 | 93 | 107 | 109 | 128 | 73 | 99 | 120 | 92 | 115 | 92 | 103 |
Days Payable | 49 | 59 | 54 | 44 | 72 | 44 | 66 | 58 | 56 | 83 | 67 | 75 |
Cash Conversion Cycle | 106 | 61 | 85 | 88 | 89 | 69 | 101 | 117 | 83 | 77 | 70 | 78 |
Working Capital Days | 53 | 10 | 18 | 26 | 32 | 25 | 57 | 43 | 31 | 35 | 39 | 36 |
ROCE % | 40% | 41% | 42% | 40% | 39% | 42% | 37% | 26% | 24% | 26% | 27% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Nov - Newspapers publications of standalone Unaudited Financial Results for the quarter and half year ended on 30-09-2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today On 05-11-2024, Inter-Alia To Approved Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.
5 Nov - Approval of unaudited financial results for Q2 2024.
- Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2024. 5 Nov
-
Board Meeting Intimation for Board Meeting Intimation For Inter-Alia, To Take On Record The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.
28 Oct - Board meeting on November 5 for financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations, 2018 for the quarter ended on 30.09.2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
JPL manufactures and markets pharmaceutical formulations in India and internationally across 13 countries. It promotes 85 brands across 1 Lac+ doctors regularly. Company has 1,000+ stockists and its reach extends to 4 Lac+ pharmacies across the globe. JPL caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.